NCT05009680View on ClinicalTrials.gov

A Single and Repeat Dose Trial in Participants With Hepatic Impairment

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

July 18, 2022

Study Completion Date

July 4, 2023

Conditions
Hepatic Impairment
Interventions
DRUG

GB1211

GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day

DRUG

Placebo

Placebo is administered orally twice a day

Trial Locations (4)

1000

COAMC Medical, Sofia

1407

Gastroenterology Clinic, Lozenets district, Sofia

1431

"Diagnostic-Advisory center 'ALEKSANDROVSKA Ltd", Sofia

1527

University Multiprofile Hospital, Clinic of gastroenterology, Sofia

Sponsors

Lead Sponsor

Galecto Biotech AB

Collaborators (1)

Comac Medical
All Listed Sponsors
collaborator

Comac Medical

INDUSTRY

lead

Galecto Biotech AB

INDUSTRY

NCT05009680 - A Single and Repeat Dose Trial in Participants With Hepatic Impairment | Biotech Hunter | Biotech Hunter